CLINICAL_TRIALS
trial_result
· 2022-04-04
Clinical Trial Update: Donafenib for Recurrent Cervical Cancer [Phase 2]
Summary
Phase 2 clinical trial update for donafenib in recurrent cervical cancer (includes various cervical cancer states and outcome considerations).
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Lei Li | Conditions: Targeted Therapy, Chemotherapy | Phase 2 | Status: UNKNOWN